The landscape of home-based care is shifting rapidly as providers balance the need for aggressive scale with the operational friction of integrating legacy systems. The Pennant Group (Nasdaq: PNTG) is currently navigating this tension, signaling a renewed interest in joint ventures and mergers and acquisitions even as it works through the complexities of its Pennant Group Amedisys integration.
Following a significant expansion into the Southeast, the Eagle, Idaho-based holding company is focusing on a disciplined growth strategy. By targeting “tuck-in” acquisitions and strategic partnerships with integrated health systems, Pennant aims to bolster its footprint in home health and hospice services without compromising the stability of its current operations.
This strategic pivot comes on the heels of a $146.5 million acquisition of home health and hospice assets divested during UnitedHealth Group’s (NYSE: UNH) acquisition of Amedisys. The deal, which closed in October 2025, added 54 locations across Alabama, Georgia, and Tennessee to Pennant’s portfolio, significantly expanding its presence in key markets.
Navigating the Amedisys Integration
Integrating dozens of care centers is rarely a seamless process, and Pennant leadership has been transparent about the hurdles involved. The company is currently executing its transition in “operational waves,” with two of five waves already migrated onto Pennant’s internal systems. The full integration process is expected to continue through October.
A primary challenge during such transitions is the migration of Electronic Medical Records (EMR). Brent Guerisoli, CEO and chairman of Pennant, noted that maintaining patient census during an EMR transition can be difficult, particularly when compounded by seasonal admission dips and severe weather events, such as those experienced in January.
Despite these disruptions, Guerisoli reported that the company has successfully rebounded, increasing its total census beyond the levels recorded at the time of the acquisition. He expressed confidence in the company’s trajectory, stating that the transition is progressing in line with expectations and that the outlook for the company in the Southeast remains positive.
Strategic Expansion via Joint Ventures
While the Amedisys integration remains the primary focus, Pennant is not pausing its growth ambitions. John Gochnour, president and chief operating officer, indicated that the company is actively considering a pipeline of joint ventures (JVs) and smaller acquisitions that meet specific, disciplined criteria.
The appeal of joint ventures is particularly strong among hospitals. According to Gochnour, hospitals are increasingly receptive to these partnerships as they struggle with labor shortages and the need to prioritize high-acuity patients who require intensive inpatient care. By partnering with an expert in home-based services, hospitals can more efficiently transition patients to lower-acuity settings, improving bed turnover and patient flow.
This “expert partner” model allows Pennant to grow its reach while sharing the operational risks associated with labor management and clinical compliance in the home health sector.
Scaling Leadership and Financial Growth
Rapid acquisition requires a corresponding surge in leadership capacity. To support its 2025 expansions, Pennant has invested heavily in its internal leadership pipeline. The company added 101 CEOs in training to its development program in 2025, followed by an additional 47 in early 2026.
the company elevated 11 local CEOs and 24 other local C-level leaders in 2025 to ensure that its newly acquired locations have experienced oversight. This focus on human capital is designed to prevent the “leadership vacuum” that often plagues large-scale healthcare consolidations.
The financial results of this growth strategy are evident in the company’s recent performance. In the first quarter of 2026, Pennant reported total revenue of $285.4 million, representing a 36% increase year-over-year. The home health and hospice segment was a primary driver of this growth, contributing $229.1 million, a 43% increase compared to the first quarter of 2025.
Regulatory Tailwinds and Payer Partnerships
Pennant is also positioning itself to benefit from a shifting regulatory environment. Leadership has expressed support for the second Trump administration’s intensified focus on rooting out fraud, waste, and abuse within the healthcare system. While Gochnour cautioned that some enforcement tools can be “blunt instruments” and urged a more nuanced approach, he noted that aggressive enforcement often creates opportunities for compliant providers.
In markets like Arizona and California, where enforcement actions against “poor actors” have been particularly aggressive, Pennant believes its long-standing reputation for clinical quality and compliance will allow it to capture market share as non-compliant agencies are removed from the ecosystem.
Parallel to regulatory shifts, the company is strengthening its relationships with “big payers.” By investing in a dedicated payer relationship team, Pennant has advanced its negotiations with major insurance providers and reported favorable, Medicare-like reimbursement rates under its managed care contracts. This focus on payer diversification is critical for maintaining margins in an era of fluctuating government reimbursement rates.
As Pennant continues to refine its operating model, the company remains focused on the final phases of its system migration. The next major milestone for the organization will be the completion of the Amedisys asset integration, scheduled for October 2026.
Do you believe the trend toward joint ventures between hospitals and home health providers will become the standard for managing patient acuity? Share your thoughts in the comments below.